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ABSTRACT
Background. This study evaluated the influence of circulating anti-HLA antibodies on
outcomes of 97 liver allografts from deceased donors.
Methods. Human leukocyte antigen (HLA) antibody screening was performed by both
complement-dependent cytotoxicity (CDC) and multiparameter Luminex microsphere-
based assays (Luminex assay).
Results. The agreements between T- and B- cell CDC and Luminex assays were 67%
and 77% for pre- and posttransplant specimens, respectively. Graft dysfunction was not
associated with either positive pretransplant CDC or Luminex panel-reactive antibody
(PRA) values. Likewise, positive posttransplant T- or B- cell CDC PRA values were not
associated with graft dysfunction. In contrast, posttransplant Luminex PRA values were
significantly higher among patients with graft dysfunction compared with subjects with
good outcomes (P  .017).
Conclusion. Posttransplant monitoring of HLA antibodies with Luminex methodology
allowed identification of patients at high-risk for poor graft outcomes.ALTHOUGH human leukocyte antigen (HLA) sensiti-zation has been shown to represent a significant risk
factor in kidney transplant, it is not yet clear whether this
holds true for liver transplantation.1,2 The objectives of this
study were to analyze liver recipients for the presence of
alloantibodies using complement-dependent cytotoxicity
(CDC) and Luminex assays to determine whether this
sensitization poses a risk to the liver allograft.
MATERIALS AND METHODS
Patients
This study included 97/112 consecutive recipients of liver transplan-
tations from deceased donors between October 1998 and June
2000. We included only patients with 2 posttransplant serum
specimens. The 518 serum samples were drawn at days 0, 7, 30, 90,
180, 360, or eventually at 18 months; as well as on the day of any
liver biopsy. The follow-up time was 5 years. All recipients received
triple-drug therapy and rejection episodes were biopsy proven.
Graft dysfunction was defined as transplant failure for any reason,
patient death or rejection occurrence.
Lymphocytotoxicity
HLA antibodies in serum specimens were detected using NIH
standard and AHG protocols. HLA class I and II panel-reactive
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15 phenotyped B cells, respectively. Both panels represented
HLA-A, -B, -DR and -DQ antigen specificities commensurate with
the frequency of antigens displayed in our population. Recipient
sera were tested against T and B panel cells before and after
dithiothreitol treatment and against B cells before and after pooled
platelet absorption. Recipient sera reacting to 10% of either the
T or B panel cells were considered positive.
Luminex Methodology
HLA antibodies were detected using multiparameter Luminex
microsphere-based assays (Tepnel Lifecodes Corporations, Stam-
ford, Conn) according to the manufacturer’s guidelines. A positive
result was defined when the average adjusted values was 1000
median fluorescence intensity. Recipient sera reacting with 10%
of either the HLA class I or II molecules (Lifecodes ID class I or
II PRA kits) were considered to be positive.
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Donor and recipient HLA class I and II were performed by
standard microlymphocytotoxicity and by DNA-based polymerase
chain reaction with sequence-specific primer techniques respec-
tively (One Lambda, Inc., Canoga Park, Calif).
Statistical Analysis
The Quicktype for Lifematch (version 2.4) program (Tepnel Life-
codes) was used for data analysis, including determination of
antibody specificities. Association of test results with-rejection
episodes and/or graft loss was analyzed using Fisher exact test and
repeated analysis of variance measures.
RESULTS
Comparison of Luminex %PRA and CDC %PRA
The agreements betweenT- andB-cell CDCandLuminex assays
were 77% (75/97) and 67% (65/97) for pre- and posttransplant
specimens, respectively. Because both CDC and Luminex assays
were associated with posttransplant events, no attempts were
made to resolve discrepant assay results.
Pretransplant Monitoring
Both techniques failed to show differences among patient
groups who had positive %PRA values and graft dysfunc-
tion at 60 months: 4/57 -(7.0%) and 17/57 -(29.8%) for CDC
%PRA and Luminex %PRA respectively. They were com-
pared with subjects with positive %PRA values and good
outcomes: 4/40 (10.0%) and 7/40 -(17.5%) for CDC %PRA
and Luminex %PRA, respectively.
Anti–donor-specific antibodies could not be identified by
CDC for any of the 8 patients with pretransplant positive
PRA values. In contrast, 10/24 patients with pretransplant
positive PRA values displayed donor-specific immunoglob-
ulin (Ig)G anti-HLA class I or II antibodies. Six of them
(60.0%) had uneventful courses after transplantation; 2
(20.0%), rejection episodes within 40 days; and 2 (20.0%)
graft loses within 10 days.
Posttransplant Monitoring
Luminex PRA values were significantly higher among pa-
tients who had positive %PRA values and graft dysfunction
within 60 months (37/57; 64.9%) compared with positive
%PRA values and good outcome (17/40; 42.5%; P  .020).
n contrast, no difference was observed for positive CDC
PRA values (24/57 [42.1%] vs 18/40 [45.0%]; P  .469,
espectively).
Anti–donor-specific antibodies were identified by the
uminex technique for 37/53 (68.8%) patients with post-ransplant positive PRA values. Follow-up of those patients
howed donor-specific antibodies (DSA) to disappear in 6
onths posttransplantation in 23 patients (62.2%). Among
hem, 10 recipients (43.5%) had uneventful outcomes, 7
30.4%) experienced 1 rejection episode, 1 (4.3%), multiple
ejection episodes, and 5 (21.7%) lost their grafts. In
ontrast, among the 14 patients (37.8%) who presented
ersistent DSA after 6 months posttransplantation, only 2
14.3%) had uneventful outcomes and 12 (85.7%) experi-
nced multiple rejection episodes (n 7) or lost their grafts
n  5).
DISCUSSION
Comparing CDC and Luminex methodologies to detect
anti-HLA antibodies, we associated their presence with
clinical outcomes after liver transplantation. We did not
observe any association of poor graft outcomes with the
presence of preformed anti-HLA class I/II antibodies de-
tected by either CDC or Luminex methodologies. One
possible explanation for this lack of correlation could be our
relatively small series of 97 cases. Also, the outcomes of
livers transplanted in the presence of preformed anti-HLA
antibodies are much less predictable than those observed in
kidney transplantations which are clearly susceptible to
antibody-mediated injury.1,2
Despite the many conflicting studies in liver transplanta-
tion concerning poor graft outcomes in the presence of
preformed anti-HLA antibodies,3 there are a paucity of
ata regarding the outcomes of liver graft function in the
resence of anti-HLA antibodies posttransplantation. In
his series of 97 liver transplantations, we showed a highly
ignificant association between graft dysfunction and post-
ransplant luminex %PRA values.
In conclusion, the findings presented herein revealed that
retransplant anti-HLA antibodies were not relevant for
raft outcomes, but that monitoring of posttransplant HLA
ntibodies with Luminex methodology allowed us to detect
atients with greater risk of graft dysfunction.
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